Skip to main content.

Wei Cui, MD

Wei Cui portait
Professor, Pathology and Laboratory Medicine
wcui@kumc.edu

Professional Background

After graduation from medical school, I worked as a research assistant in Neuroendocrine laboratory at China Medical University from 1992-1995. Then I went to seek a master’s degree in Biochemistry at the University of Kansas and meanwhile worked as a research assistant on my Master Thesis studying on functions of Drosophila Kinesin like protein (KLP38B) from 1996 to 1997. After finishing my master’s degree, I worked as a research assistant focusing on cancer research in the department of Pathology and Laboratory Medicine at the University of Kansas Medical Center for two years. Later, I moved to in the department of Microbiology and worked on cytokine response to gram-positive and gram-negative bacteria in mouse macrophages as a post-doctoral research associate for the next two years. Then I joined Great Plain Laboratory as a research chemist in R andamp; D section briefly. I moved to Dr. Scott Hawley’s lab at the Stowers Institute for Medical Research and worked on function analysis of Drosophila chemokinesin protein as a research specialist from 2002 to 2005.
After more than 10 years’ work on medical research, I had strong desire to go back medical field to provide direct patient care. I completed residency training in Anatomic and Clinical Pathology in the department of Pathology and Laboratory Medicine at the University of Kansas Medical Center from 2005 to 2009 and completed hematopathology fellowship training at the University of Texas MD Anderson Cancer in 2010. Then I joined the department of Pathology and Laboratory Medicine at the University of Kansas Medical Center as an Assistant Professor in 2010 and was promoted to an Associated Professor in 2015. I also became a medical director in the University Medical Center Cancer Center Overland Park Laboratory and West Laboratory in 2014 and in Clinical Flow Cytometry Laboratory in 2015. Currently, our Clinical Flow Cytometry Laboratory provides over 6,000 tests in diagnosis of leukemia, lymphoma, myeloma and minimal residual disease each year.
My clinical practice includes surgical pathology and hematopathology. My surgical pathology interest focuses on Gastrointestinal Pathology and Obstetric Gynecology Pathology. Hematopathology practice includes morphologic evaluation and flow cytometric analysis of bone marrows, peripheral blood, body fluids, and lymph nodes.

Education and Training
  • MA, Biochemistry, University of Kansas
  • Clinical Fellowship, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Residency, Pathology and Laboratory Medicine, The Univiersity of Kansas Medical Center, Kansas City, KS
  • Post Doctoral Fellowship, Microbiology, The University of Kansas Medical Center, Kansas City, KS
Licensure, Accreditations & Certifications
  • Anatomic and Clinical Pathology, American Board of Pathology
  • Certificate of Renewal, KANSAS STATE BOARD of HEALING ARTS
  • Hematology, American Board of Pathology
Professional Affiliations
  • CAP, Diagnostic Immunology & Flow Cytometry Committee, Member, 2022 - Present
  • International Clinical Cytometry Society, Education Committee, Member, 2020 - Present
  • Hospital Based Department Cohort Nominating Committee, Hospital Based Department Cohort Nominating Committee, Member, 2019 - 2020
  • Department Compensation Plan Committee , Department Compensation Plan Committee , Member, 2016 - Present
  • Clinical Competency Committee of Pathology Residency Program, Clinical Competency Committee of Pathology Residency Program, Member, 2013 - Present
  • Society of Hematopathology, Member, 2013 - Present
  • Hematopathology Fellowship Committee , Hematopathology Fellowship Committee , Member, 2012 - Present

Research

Overview

My research interest includes assessment of different cytogenetic abnormalities as prognostic markers in myeloid neoplasms, evaluation of biomarkers and their prognostic values in lymphomas and myeloid neoplasms, flow cytometry application in prognostic marker evaluation in lymphoma and minimal residual disease assessment in myeloid neoplasms, and quantity control and test utilization of flow cytometric assay. I have provided my clinical expertise as a surgical pathologist to evaluate morphologic features in different disease models and work collaboratively with different groups of laboratory scientists on animal models and human materials.

Publications
  • Gao, Linlin , Saeed, Azhar , Golem, Shivani , Zhang, Da , Woodroof, Janet, McGuirk, Joseph , Ganguly, Siddhartha , Abhyankar, Sunil , Lin, Tara ., L. , Cui, Wei. 2020. MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. International Journal of Laboratory Hematology
  • Brown, L, Zhang, D, Cui, W. 2020. Flow Cytometric Immunophenotypic Study of Monocytes and Granulocytes in Myeloid Neoplasms and Reactive Conditions: A Single Institution Experience and Literature Review. Ann Clin Lab Sci, 50 (3), 327-332
  • Rivas, E, Plapp, F., V, Cui, W. 2020. Flow Cytometric, Morphologic, and Laboratory Comparative Study in Patients With Leukocytosis and Cytopenia. Am J Clin Pathol
  • Gao, L, Harbaugh, B, Parr, K, Patel, P, Golem, S, Zhang, D, Woodroof, J, Cui, W. 2021. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.. American journal of clinical pathology
  • McGowan, P, Hyter, S, Cui, W, Plummer, R., M, Godwin, A., K, Zhang, D. 2021. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.. International journal of laboratory hematology
  • Pennipede, D, Mohyuddin, G., R, Hawkins, R, Ganguly, S, Shune, L, Ahmed, N, Mohan, M, Cui, W, Mahmoudjafari, Z, McGuirk, J, Atrash, S, Abdallah, A., O. 2021. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).. European journal of haematology